Cannabichromene Safety in Rheumatoid Arthritis

Paused · Phase 1/Phase 2

Conditions studied: Arthritis, Rheumatoid

In brief

For this quantitative study, the investigators will collect data on human safety and side-effects of Cannabichromene (CBC) and whether CBC reduces blood inflammatory markers and Rheumatoid Arthritis (RA) disease activity. The participants will participate in an ABAB design with 2 doses of CBC across the A phases. They will attend 5 in-person clinic visits where they will have physical evaluations, complete self-report forms, and have blood drawn for the following tests: hs-CRP, ESR, IL-6, TNF, Complete Blood Count \[CBC\], and CMP.

Key facts

Study ID
NCT07087938
Run by
Crystal Lederhos Smith
People needed
25
Starts
2028-07-15
Expected to finish
2030-05-31
Last updated by the study team
2025-07-28

Who can join

Age: 21 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.